Skip to main content
Premium Trial:

Request an Annual Quote

Sophia Genetics, ArcherDx Ink Deal to Combine Technologies

NEW YORK (GenomeWeb) — Sophia Genetics and ArcherDx today announced that they have formed a partnership to combine their respective technologies to provide an integrated analytical and next-generation sequencing sample preparation offering for cancer research.

Under the terms of the deal, Sophia will incorporate ArcherDx's FusionPlex, VariantPlex, and Reveal ctDNA kits into its Data-Driven Medicine analytical platform, and offer the combined solutions to its network of more than 215 hospital and laboratory customers globally. 

"By joining forces, ArcherDX and Sophia Genetics are enabling international laboratories of all sizes using [Sophia's artificial intelligence technology] to access and report on cutting-edge applications that ArcherDX has developed, including gene fusions, liquid biopsies, and immune repertoire profiling," ArcherDx CEO Jason Myers said in a statement.

The companies said their partnership launches immediately. Additional terms of the arrangement were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.